HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patrick Burnett Selected Research

Molluscum Contagiosum

10/2021Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials.
3/2021Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
1/2021A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
12/2020Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patrick Burnett Research Topics

Disease

4Molluscum Contagiosum
10/2021 - 12/2020
1Warts (Wart)
10/2021
1Erythema
03/2021
1Pruritus (Itching)
03/2021
1Pain (Aches)
03/2021
1Virus Diseases (Viral Diseases)
01/2021
1Basal Cell Carcinoma (Rodent Ulcer)
02/2013
1Melanoma (Melanoma, Malignant)
04/2011
1Hand-Foot Syndrome
01/2011
1Anorexia
01/2011
1Renal Cell Carcinoma (Grawitz Tumor)
01/2011
1Diarrhea
01/2011
1Fatigue
01/2011
1Hypertension (High Blood Pressure)
01/2011

Drug/Important Bio-Agent (IBA)

5Cantharidin (Cantharides)IBA
10/2021 - 12/2020
5Pharmaceutical PreparationsIBA
10/2021 - 12/2020
5VP-102IBA
10/2021 - 12/2020
1Phosphotransferases (Kinase)IBA
04/2011
1Sunitinib (Sutent)FDA Link
01/2011
1Tyrosine Kinase InhibitorsIBA
01/2011

Therapy/Procedure

2Therapeutics
02/2013 - 04/2011